CMND

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel, non-hallucinogenic,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today commended President Donald J. Trump's Executive Order signed on April 18, 2026, titled Accelerating Medical Treatments for Serious Mental Illness, which directs the U.S. Food and Drug Administration (FDA) to prioritize review processes for certain psychedelic drugs designated as breakthrough therapies and expands patient access pathways. "We are pleased to see psych

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced that CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage admin

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board ("DSMB") has completed its review and issued a positive recommendation to continue the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for the treatment of Alcohol Use Disorder ("AUD"). The positive DSMB recommendation follows the successful completion of the third cohort and is based

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to dat

EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)

EFFECT - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disord

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction. The patent application, filed with the Indian Patent Office, forms part of the Company's expanding global intellectual property portfolio and builds upon its exclusive worldwide licens

POS AM - Clearmind Medicine Inc. (0001892500) (Filer)

POS AM - Clearmind Medicine Inc. (0001892500) (Filer)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This positive progress follows the Company's recent announcement on March

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, March 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide (PEA), sourced through the Company's partnership with NeuroThera Labs Inc. (TSXV:NTLX), with leading classic and innovative psychedelic compounds. The published patents protect in

SCHEDULE 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)